NYSE:DPLO - Diplomat Pharmacy Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.04 -0.07 (-1.37 %) (As of 05/27/2019 09:02 AM ET)Previous Close$5.11Today's Range$5.01 - $5.1852-Week Range$4.97 - $28.74Volume363,409 shsAverage Volume856,998 shsMarket Capitalization$376.54 millionP/E Ratio25.20Dividend YieldN/ABeta0.69 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company primarily focuses on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. It also offers PBM services, including electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail pharmacy claims management, specialty pharmacy claims management, Medicare Part D services, benefit design consultation, drug review and analysis, consulting services, data access, and reporting, information analysis, and preferred drug management programs to managed care organizations, self-insured employer groups, unions, and third-party healthcare plan administrators and worker's compensation payers. The company was founded in 1975 and is headquartered in Flint, Michigan. Receive DPLO News and Ratings via Email Sign-up to receive the latest news and ratings for DPLO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Drug stores & proprietary stores Sub-IndustryN/A SectorRetail/Wholesale Current SymbolNYSE:DPLO Previous Symbol CUSIPN/A CIK1610092 Webhttp://www.diplomatpharmacy.com/ Phone888-720-4450Debt Debt-to-Equity Ratio1.00 Current Ratio1.00 Quick Ratio0.66Price-To-Earnings Trailing P/E Ratio25.20 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.49 billion Price / Sales0.07 Cash Flow$4.5818 per share Price / Cash Flow1.10 Book Value$6.24 per share Price / Book0.81Profitability EPS (Most Recent Fiscal Year)$0.20 Net Income$-302,270,000.00 Net Margins-5.85% Return on Equity1.38% Return on Assets0.52%Miscellaneous Employees2,335 Outstanding Shares74,710,000Market Cap$376.54 million Next Earnings Date8/5/2019 (Estimated) OptionableOptionable Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions What is Diplomat Pharmacy's stock symbol? Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO." How were Diplomat Pharmacy's earnings last quarter? Diplomat Pharmacy Inc (NYSE:DPLO) announced its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by $0.26. The firm earned $1.26 billion during the quarter, compared to analysts' expectations of $1.17 billion. Diplomat Pharmacy had a negative net margin of 5.85% and a positive return on equity of 1.38%. The company's revenue for the quarter was down 6.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.01) EPS. View Diplomat Pharmacy's Earnings History. When is Diplomat Pharmacy's next earnings date? Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Diplomat Pharmacy. What guidance has Diplomat Pharmacy issued on next quarter's earnings? Diplomat Pharmacy issued an update on its FY 2019 earnings guidance on Tuesday, May, 7th. The company provided EPS guidance of $-0.65--0.44 for the period, compared to the Thomson Reuters consensus estimate of $0.34. The company issued revenue guidance of $4.7-5 billion, compared to the consensus revenue estimate of $4.82 billion.Diplomat Pharmacy also updated its FY19 guidance to ($0.65-0.44) EPS. What price target have analysts set for DPLO? 13 brokerages have issued twelve-month price targets for Diplomat Pharmacy's shares. Their forecasts range from $6.00 to $30.00. On average, they expect Diplomat Pharmacy's share price to reach $10.25 in the next twelve months. This suggests a possible upside of 103.4% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy. What is the consensus analysts' recommendation for Diplomat Pharmacy? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 2 sell ratings, 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Diplomat Pharmacy. Has Diplomat Pharmacy been receiving favorable news coverage? News articles about DPLO stock have trended extremely negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Diplomat Pharmacy earned a media sentiment score of -4.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. Who are some of Diplomat Pharmacy's key competitors? Some companies that are related to Diplomat Pharmacy include 111 (YI), Rite Aid (RAD), Petmed Express (PETS), Taxus Pharmaceuticals (TXSP), HealthWarehouse.com (HEWA) and Dougherty's Pharmacy (MYDP). What other stocks do shareholders of Diplomat Pharmacy own? Based on aggregate information from My MarketBeat watchlists, some companies that other Diplomat Pharmacy investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), General Electric (GE), Activision Blizzard (ATVI), XOMA (XOMA), CVS Health (CVS), Cannabis Sativa (CBDS), Karyopharm Therapeutics (KPTI), Netflix (NFLX) and Servicesource International (SREV). Who are Diplomat Pharmacy's key executives? Diplomat Pharmacy's management team includes the folowing people: Mr. Brian Thomas Griffin, CEO & Chairman (Age 60)Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 67)Mr. Daniel Paul Davison, CFO & TreasurerMr. Dave Loschinskey, Chief Operating Officer (Age 48)Ms. Terri Anne Powers, VP of Investor Relations Who are Diplomat Pharmacy's major shareholders? Diplomat Pharmacy's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.43%), Dimensional Fund Advisors LP (3.02%), Northern Trust Corp (1.71%), Frontier Capital Management Co. LLC (1.46%), Cambridge Investment Research Advisors Inc. (1.08%) and FMR LLC (0.92%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Joel Saban, Philip R Hagerman and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy. Which institutional investors are selling Diplomat Pharmacy stock? DPLO stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., FMR LLC, JPMorgan Chase & Co., Cambridge Investment Research Advisors Inc., New York State Common Retirement Fund, BlackRock Inc., Frontier Capital Management Co. LLC and Northern Trust Corp. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Atul Kavthekar, Jeffrey G Park, Philip R Hagerman and Shawn Tomasello. View Insider Buying and Selling for Diplomat Pharmacy. Which institutional investors are buying Diplomat Pharmacy stock? DPLO stock was bought by a variety of institutional investors in the last quarter, including Stephens Inc. AR, Morgan Stanley, Trexquant Investment LP, Dimensional Fund Advisors LP, Laurion Capital Management LP, Charles Schwab Investment Management Inc., Renaissance Technologies LLC and Wells Fargo & Company MN. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy. How do I buy shares of Diplomat Pharmacy? Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Diplomat Pharmacy's stock price today? One share of DPLO stock can currently be purchased for approximately $5.04. How big of a company is Diplomat Pharmacy? Diplomat Pharmacy has a market capitalization of $376.54 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Diplomat Pharmacy employs 2,335 workers across the globe. What is Diplomat Pharmacy's official website? The official website for Diplomat Pharmacy is http://www.diplomatpharmacy.com/. How can I contact Diplomat Pharmacy? Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected] MarketBeat Community Rating for Diplomat Pharmacy (NYSE DPLO)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 308 (Vote Outperform)Underperform Votes: 331 (Vote Underperform)Total Votes: 639MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/27/2019 by MarketBeat.com StaffFeatured Article: What Does Beta Mean In Stock Selection Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.